Eric Lindquist

HOME  |  TEAM  | 

Eric Lindquist

Chief Business Officer

Eric has over 25 years of experience in the diagnostic and pharmaceutical industries. Prior to joining resistanceBio, he was the Chief Business Officer at Celcuity Inc. he helped initiate and launch several phase II clinical trials and licensed a phase 3 ready asset called Gedatolisib (PI3K/mTOR inhibitor) from Pfizer. He previously served as Global Vice President of Oncol at Natera, where he launched Signatera to the pharmaceutical industry. He also served as the Global Vice President of Customer and Companion Diagnostics at Asuragen, a molecular testing company, and as the Director of Business Development and Alliances for Companion Diagnostics at Roche Diagnostics. Early in his career, he was a sales specialist for molecular and companion diagnostics at Abbott Laboratories. He also spent time at Johnson & Johnson’s Veridex division, where he managed co-development partnerships with pharmaceutical and diagnostic companies.

Email: Eric Lindquist